BICDL1

Across TCGA pan-cancer cohorts, BICDL1 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated BICDL1 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher BICDL1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated BICDL1 expression acts as an unfavorable survival marker.

CCRCC and HNSC are the cancer types where BICDL1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.411	0.858	.002	40	view →
HNSC	OS	Quartile	All	0.764	1.000	.026	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

BICDL1–CCRCC (DFS)

Open the CCRCC breakdown →